To view or add a comment, sign in Finerenone is a non-steroidal mineralocorticoid receptor antagonist (MRA) that is currently been approved for adults with chronic kidney disease (CKD) in type 2 diabetes (T2D) setting and shown to reduce ESKD, CV-related death and hospitalization for heart failure (FIDELIO-DKD, FINEARTS-HF trials)
Common side effects of semaglutide Common side effects may include nausea, vomiting, diarrhea, and constipation
Lysosome trafficking and signaling in health and neurodegenerative diseases
Antioxidant therapy reduced the loss of rubrospinal neurons by approximately 50%
We offer scientifically proven treatments using US FDA approved technology
Current NHS challenges: Demand for GLP-1 receptor agonists substantially exceeds supply, with many NHS areas implementing waiting lists or restrictive prescribing policies